Oncolytics to meet FDA to discuss trial approval pathway
Oncolytics Biotech announced plans to hold a Type D meeting with the FDA to design a registrational study for its REO 033 colorectal cancer trial. This regulatory step targets accelerated approval and reflects ongoing confidence in the company's clinical data and immunotherapy pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day